Every day, thousands of babies are born too early—and with that early birth comes a dramatically higher risk of deadly childhood cancers like leukemia and retinoblastoma. Current treatments to prevent preterm labor often fail, leaving families vulnerable to lifelong medical and financial devastation. ViaTechMD’s Cervical Stabilization Device (CSD) is a breakthrough, noninvasive solution that directly targets the physical cause of many preterm births. We’ve already raised $4.2M, secured 35 patents, and are ready to begin FDA trials—but we need $4M now to prove this device works and bring it to market. Without urgent funding, we risk losing a powerful opportunity to stop preventable cancers before they start.
SHARE:
Babies born too early face far more than just a fragile start—they face a lifetime of elevated health risks, including aggressive childhood cancers. Research shows that preterm infants are significantly more likely to develop cancers like acute myeloid leukemia (2x risk), retinoblastoma (3x), and germ cell tumors (nearly 6x). These cancers are rare, fast-moving, and devastating. The connection is clear: when babies are born before their immune and cellular systems are fully developed, they’re left vulnerable to abnormal cell growth and long-term health complications.
At the heart of many preterm births is a silent problem: the cervix softens or opens too soon. Our Cervical Stabilization Device (CSD) is a simple, noninvasive solution designed to gently brace the cervix and help prevent early labor—without surgery, without hormones, and without guesswork. Backed by science and built for real-world use, especially in low-resource settings, the CSD offers hope where current treatments fall short. With over 3,000 babies lost to preterm birth every day, we believe this device could be the difference between a lifetime of risk—and a healthy start.
Our regulatory path is in expert hands. Leading our FDA negotiations is Dr. Benjamin Fisher, former Director of the FDA’s Division of Reproductive, Gastro-Renal, and Urological Devices. Now part of our team, Dr. Fisher brings unmatched experience to help guide our device through approval—so we can move quickly to protect more pregnancies and save more lives.
ViaTechMD has already raised $4.2 million from founders, friends, and family—enough to build our Cervical Stabilization Device (CSD), complete successful human fitment studies, secure 35 global patents, and set up scalable manufacturing. Now, we’re seeking up to $4 million in Series A funding to move from prototype to clinical proof and prepare for market entry. Phase one ($2M) will fund FDA-required clinical trials and regulatory work; phase two ($2M) will support global expansion and commercialization.
These funds will power critical next steps: FDA Breakthrough Device designation, biocompatibility testing, a 25-patient clinical trial, expert regulatory and legal support, and the production of clinical-grade CSD kits. We’ll also maintain our global patent portfolio and begin securing international approvals to reach patients worldwide. With a low-cost, noninvasive solution to help prevent preterm birth, the CSD has the potential to save thousands of lives—and this is our moment to prove it works and bring it to the women who need it most.
ViaTechMD is preparing for a critical step: an FDA-approved Early Feasibility Study (EFS), where our Cervical Stabilization Device will be tested in real pregnant patients for the first time. This small but powerful clinical trial will focus on women at high risk of preterm labor—the leading cause of newborn death and serious long-term complications, including cancers like leukemia and retinoblastoma. The goal is clear: prove the device is safe and effective at preventing early labor, potentially transforming outcomes for thousands of babies.
Completing this study is essential to unlocking follow-on funding from investors and donors who are waiting for clinical proof. But at this early stage, traditional funding sources—like VCs and government grants—are out of reach. That’s why support from Music Beats Cancer is not just helpful, but vital. Every dollar brings us closer to validating our breakthrough and preventing the devastating toll of preterm birth for families everywhere.
If our device is lost in the “Valley of Death” due to lack of early-stage funding, society will continue paying the high price of preventable diseases—especially in underserved communities. Preterm birth affects 1 in 10 U.S. babies each year, with even higher rates among Black mothers and in rural areas lacking maternity care. It’s not just an issue of survival—preterm birth significantly increases a child’s risk of developing devastating cancers like acute myeloid leukemia, retinoblastoma, and hepatoblastoma, often before age five. The cost of treating just one child with cancer can exceed $800,000, a burden that disproportionately falls on Medicaid and low-income families.
Current options to prevent early labor—surgical stitches and hormone shots—fail to address the physical strain on the cervix that triggers many preterm births. Our Cervical Stabilization Device is built to solve that exact problem. With early funding, we can generate the clinical evidence needed to unlock larger investments and bring this life-saving innovation to market. Without it, we miss the chance to stop preventable cancers before they start and leave already-vulnerable families to shoulder a crisis we could have prevented.
Founder & Managing Member
Ben is the inventor of our device and has over 48 years of experience in the design, engineering, and development of materials, technologies, and products, including during his tenure at Chrysler. His expertise encompasses C-suite business negotiations, licensing, and patent and intellectual property development. In 1987, Ben and his wife faced challenges related to preterm birth with their youngest son and again with their youngest daughter in 1999. Since then, they have been dedicated to the ViaTechMD mission and research that is now supported by recent scientific discoveries in the field of human reproduction. This research has uncovered the significance of biomechanical forces acting on the lower uterine segment and cervix, which are now understood to serve a primary role in the progression of the birthing process. With this insight, Ben designed, constructed, and lab-tested our initial device prototypes, including those used in our successful human fitment studies. Additionally, Ben is responsible for developing our highly efficient and effective business model and fostering strong relationships with our affiliates and partnering organizations.
Company Member and FDA Advisor
Dr. Fisher began his toxicology career in 1978 working with the Bureau of Radiological Health (now the Center for Devices and Radiological Health) of the Food and Drug Administration. Dr. Fisher received his PhD in developmental genetics from George Washington University, where his research utilized mammalian whole embryo culture to evaluate alterations in embryonic gene expression as biomarkers of exposure and toxicity, and their utility in predicting skeletal anomalies. Dr. Fisher joined Covance Laboratories in 1998 where, as a Principal Scientist and Study Director Manager, he was responsible for the design, conduct, and interpretation of preclinical developmental and reproductive toxicology and juvenile toxicology studies. After returning to the FDA, he became the Director of the Division of Reproductive, Gastro-Renal, and Urological Devices within the Office of Device Evaluation, providing oversight on device submission reviews and regulatory policy. In 2019 assumed the official role as Director of the Office of Health Technologies within the Office of Product Evaluation and Quality. Dr. Fisher is a member of the Society of Toxicology, the Teratology Society, and past President of the Mid-Atlantic Reproduction and Teratology Association (MARTA).
Company Member and Scientific Advisor
Dr. Murray received her PhD in Bioengineering from Arizona State University, to then become a Postdoctoral Associate at Yale University, and now holds the position of Edmondson/Crump Endowed Associate Professor for Biomedical Research and Rehabilitation Science, at Louisiana Tech University. Dr. Murray was a recipient of the highly competitive National Science Foundation “NSF” Graduate Research Fellowship and two NSF IGERT Fellowships. Dr. Murray has 20 years of research experience and biomedical engineering design. One of the driving forces behind her decision to enter the bioengineering profession was her prior experience managing a health clinic serving an at-risk population. She shares our intense desire to improve the health of women. Dr. Murray is also the Director, Integrated Neuroscience and Imaging Lab, Center for Biomedical Research and Rehabilitation Sciences, Louisiana Tech University, and is the past President, Alpha Eta Mu Beta, the International Biomedical Engineering Honor Society. Dr. Murray is a Board Member at Medical Education ProChad, Inc., and shares our intense desire to improve the health of women.
$16000 donated by Phillip Minerich
